1.College of Pharmaceutical Science，Zhejiang University of Technology，Hangzhou 310000，China；2.Cardiovascular Department，West China Hospital，Sichuan University，Chengdu 610041，China； 3.Applied Physics Department，College of Physical Science，Sichuan University，Chengdu 610041，China；4.Material Department，Dalian University of Technology，Dalian 116023，China
OBJECTIVE To detect in vitro release properties of rapamycin sustained eluting stent and to provide pharmacokinetic profile for clinical application.METHODS Rapamycin and PLGA were coated on the 316L stainless metal stent by the high pressure multilayer electronic spraying technique.The in vitro release kinetics of rapamycin sustained eluting stent were studied by a self-designed mimic cardiac pumping device.At the interval,the concentration of rapamycin on the remained stent was detected by RP-HPLC method.RESULTS The average thickness of rapamycin and PLGA coating was 5～10 μm and the average content of rapamycin was 14.39 μg.The in vitro release profile showed that rapamycin released slowly from the coating with the fast speed at the early stage and slow speed at the later stage.The cumulative release percentages were(58.48±5.67)% for 12 d and(60.66±5.75)% for 30 d.The release mechanism accorded to Hixson-Crowell erosion model.CONCLUSION The self-designed device for mimic cardiac pumping is suitable to study the in vitro release of drug eluting stent.And the prepared rapamycin sustained eluting stent shows a good control release profile according with the proliferation of vascular smooth muscle cells.
CHEN Yu-cheng;XIONG Su-in;XING Ho-yng;ZENG Zhi;QI Min. In Vitro Release of Rapamycin Sustained Eluting Stent Detected by a New Designed Circulating Device [J]. Chinese Pharmaceutical Journal, 2008, 43(09): 688-691
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] SCHIELE T M. Current understanding of coronary in-stent restenosis[J] .Z Kardiol，2005，94(11)：772-790.
[2] HOFFMANN R，MINTZ G S，DUSSAILLANT G R，et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study[J] .Circulation，1996，94(6):1247-1254.
[3] MORICE M C，SERRUYS P W，SOUSA J E，et al. Randomized study with the sirolimus-coated bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization[J] .N Engl J Med，2002，346：1773-1780.
[4] GRUBE E，SILBER S，HAUPTMANN K E，et al. TAXUS I： six- and twelve-month results from a randomized，double-blind trial on a slow-release paclitaxeleluting stent for de novo coronary lesions[J] .Circulation，2003，107： 38-42.
[5] XIONG S B，LU B. Study on the release profile of fluorouracil microspheres in vitro[J] .China Pharm（中国药师），2003，6（5）：261-262.
[6] LINCOFF A M，TOPOL E J，ELLIS S G. Local drug delivery for the prevention of restenosis： fact，fancy，and future[J] . Circulation，1994，90：2070-2084.
[7] LI R J，LI J，CHEN Y C，et al. Drug eluting stents in coronary artery disease： A meta-analysis[J] .Chin J Evidence-Based Med（中国循证医学杂志），2005，5(2)： 519-535.
[8] FRANK A，SUBBU S V，et al.In vitro study of release mechanisms of paclitaxel and rapamycin from drug-incorporated biodegradable stent matrices[J] .J Controlled Release，2004，98：67-74.
[9] YIN M，YUAN Y，LIU C S. Preparation and characterization of drug contained ethylene-vinyl alcohol copolymer coatings on 316L stainless steel[J] .J East Chin Univ Sci Technol(Nat Sci Edit)(华东理工大学学报自然科学版)，2005，31(3) ：386-389.
[10] CRRISTEN T，VERIN V，BOCHATON-PIALLAT M，et al. Mechanisms of neointima formation and remodeling in the porcine coronary artery[J] .Circulation，2001，103(6)：882-888.
